NFKB1 and colorectal carcinoma: Given that PDXs have been found to accurately predict patient responses to conventional as well as novel therapeutics, these models provide a valuable platform for investigating patient responses to drugs and treatments, thus elucidating the NF-κB signaling pathway in CRC, mechanisms of resistance, and facilitating personalized medicine [55,76] (Figure 5).